他汀类药物用于成人心血管疾病一级预防:美国预防服务工作组更新证据报告与系统评价
该系统评价纳入26项研究:22项随机临床试验(N=90624)比较他汀与安慰剂或无他汀,1项试验(n=5144)比较他汀强度,3项观察性研究(n=417523)报告不良事件。他汀显著降低全因死亡(RR 0.92,95%CI 0.87-0.98;ARD -0.35%,95%CI -0.57%至-0.14%)、卒中(RR 0.78,95%CI 0.68-0.90;ARD -0.39%,95%CI -0.54%至-0.25%)、心肌梗死(RR 0.67,95%CI 0.60-0.75;ARD -0.85%,95%CI -1.22%至-0.47%)和复合心血管结局(RR 0.72,95%CI 0.64-0.81;ARD -1.28%,95%CI -1.61%至-0.95%);心血管死亡关联未达统计学显著(RR 0.91,95%CI 0.81-1.02)。他汀未显著增加严重不良事件、肌痛或丙氨酸氨基转移酶升高风险;总体糖尿病风险未显著增加,但1项试验中高强度他汀与糖尿病风险显著增加相关。
要点
- 无既往心血管事件的成人中,他汀与全因死亡风险降低相关(RR 0.92,95%CI 0.87-0.98;ARD -0.35%,95%CI -0.57%至-0.14%)。
- 他汀与心肌梗死(RR 0.67,95%CI 0.60-0.75)、卒中(RR 0.78,95%CI 0.68-0.90)和复合心血管结局(RR 0.72,95%CI 0.64-0.81)风险降低相关。
- 心血管死亡关联未达统计学显著(RR 0.91,95%CI 0.81-1.02;ARD -0.13%)。
- 他汀未显著增加严重不良事件(RR 0.97,95%CI 0.93-1.01)、肌痛(RR 0.98,95%CI 0.86-1.11)或丙氨酸氨基转移酶升高(RR 0.94,95%CI 0.78-1.13)风险。
- 总体糖尿病风险未显著增加(RR 1.04,95%CI 0.92-1.19),但1项试验中高强度他汀与糖尿病风险显著增加相关(RR 1.25,95%CI 1.05-1.49)。
适用人群与场景
- 无既往心血管事件的成人,用于心血管疾病一级预防。
- 相对获益在人口学和临床特征定义的各亚组中一致,但75岁以上人群数据稀疏。
研究设计与关键结果
- 纳入26项研究:22项随机临床试验(N=90624,随访6个月至6年)比较他汀与安慰剂或无他汀;1项试验(n=5144)比较他汀强度;3项观察性研究(n=417523)报告不良事件。
- 他汀显著降低全因死亡风险(RR 0.92,95%CI 0.87-0.98;ARD -0.35%,95%CI -0.57%至-0.14%)、卒中风险(RR 0.78,95%CI 0.68-0.90;ARD -0.39%,95%CI -0.54%至-0.25%)、心肌梗死风险(RR 0.67,95%CI 0.60-0.75;ARD -0.85%,95%CI -1.22%至-0.47%)和复合心血管结局风险(RR 0.72,95%CI 0.64-0.81;ARD -1.28%,95%CI -1.61%至-0.95%)。
- 心血管死亡关联未达统计学显著(RR 0.91,95%CI 0.81-1.02;ARD -0.13%)。
- 他汀未显著增加严重不良事件风险(RR 0.97,95%CI 0.93-1.01)、肌痛风险(RR 0.98,95%CI 0.86-1.11)或丙氨酸氨基转移酶升高风险(RR 0.94,95%CI 0.78-1.13)。
- 总体糖尿病风险未显著增加(RR 1.04,95%CI 0.92-1.19),但1项试验发现高强度他汀与糖尿病风险显著增加相关(RR 1.25,95%CI 1.05-1.49);除此之外,他汀强度对结局无明确差异。
证据类型、等级与局限
- 证据类型:系统评价与随机临床试验(22项试验,N=90624)及观察性研究(3项,n=417523)。
- 局限:75岁以上人群数据稀疏。
对床旁实践的改变
- 在无既往心血管事件但心血管风险增加的成人中,他汀治疗用于心血管疾病一级预防与全因死亡及心血管事件风险降低相关。
指南或共识出处
- 美国预防服务工作组(USPSTF)更新证据报告与系统评价
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: A 2016 review for the US Preventive Services Task Force (USPSTF) found use of statins for primary prevention of cardiovascular disease (CVD) was associated with reduced mortality and cardiovascular outcomes.
OBJECTIVE: To update the 2016 review on statins for primary prevention of CVD to inform the USPSTF.
DATA SOURCES: Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews (to November 2021); surveillance through May 20, 2022.
STUDY SELECTION: Randomized clinical trials on statins vs placebo or no statin and statin intensity in adults without prior cardiovascular events; large cohort studies on harms.
DATA EXTRACTION AND SYNTHESIS: One investigator abstracted data; a second checked accuracy. Two investigators independently rated study quality.
MAIN OUTCOMES AND MEASURES: All-cause and cardiovascular mortality, myocardial infarction, stroke, composite cardiovascular outcomes, and adverse events.
RESULTS: Twenty-six studies were included: 22 trials (N = 90 624) with 6 months to 6 years of follow-up compared statins vs placebo or no statin, 1 trial (n = 5144) compared statin intensities, and 3 observational studies (n = 417 523) reported harms. Statins were significantly associated with decreased risk of all-cause mortality (risk ratio [RR], 0.92 [95% CI, 0.87 to 0.98]; absolute risk difference [ARD], -0.35% [95% CI, -0.57% to -0.14%]), stroke (RR, 0.78 [95% CI, 0.68 to 0.90]; ARD, -0.39% [95% CI, -0.54% to -0.25%]), myocardial infarction (RR, 0.67 [95% CI, 0.60 to 0.75]; ARD, -0.85% [95% CI, -1.22% to -0.47%]), and composite cardiovascular outcomes (RR, 0.72 [95% CI, 0.64 to 0.81]; ARD, -1.28% [95% CI, -1.61% to -0.95%]); the association with cardiovascular mortality was not statistically significant (RR, 0.91 [95% CI, 0.81 to 1.02]; ARD, -0.13%). Relative benefits were consistent in groups defined by demographic and clinical characteristics, although data for persons older than 75 years were sparse. Statin therapy was not significantly associated with increased risk of serious adverse events (RR, 0.97 [95% CI, 0.93 to 1.01]), myalgias (RR, 0.98 [95% CI, 0.86 to 1.11]), or elevated alanine aminotransferase level (RR, 0.94 [95% CI, 0.78 to 1.13]). Statin therapy was not significantly associated with increased diabetes risk overall (RR, 1.04 [95% CI, 0.92 to 1.19]), although 1 trial found high-intensity statin therapy was significantly associated with increased risk (RR, 1.25 [95% CI, 1.05 to 1.49]). Otherwise, there were no clear differences in outcomes based on statin intensity.
CONCLUSIONS AND RELEVANCE: In adults at increased CVD risk but without prior CVD events, statin therapy for primary prevention of CVD was associated with reduced risk of all-cause mortality and CVD events. Benefits of statin therapy appear to be present across diverse demographic and clinical populations, with consistent relative benefits in groups defined by demographic and clinical characteristics.
参考来源
- Chou R, Cantor A, Dana T, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022. PMID: 35997724. doi:10.1001/jama.2022.12138
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。